The subject has received another investigational agent within 21 days of the first dose of study drug
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The participant has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The participant has received another investigational agent within 14 days of the first dose of study drug
Received any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
Received any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)
mCRPC EXPANSION COHORT: The patient has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
Receipt of any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
Any other type of investigational agent within 4 weeks before the first dose of study treatment
RENAL COHORT: The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
Any other type of investigational agent within 28 days before the first dose of study treatment
Investigational agent received within 30 days prior to the first dose of study drug
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
Having received an investigational agent within 30 days prior to the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The participant has received any other type of investigational agent within 28 days before the first dose of study treatment
Treatment with any investigational agent within 28 days before the first dose of study treatment
Having received an investigational agent with 21 days of receiving the first dose of study drug on this trial
Use of any other type of investigational agent or treatment concurrently or within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any investigational agent within 28 days before the first dose of study treatment
Received any investigational agent within the 14 days before the start of study treatment (1st dose of ALT-803)